Komppanianpäällikön mukaan droonit eivät tee panssarijoukoista hyödyttömiä.

YouTube video by Unboxing Biotech

A novel PDE10A inhibitor just showed safety and efficacy in a large Phase 2 trial for acute schizophrenia. 👏 📌 PDE10A inhibitors represent a non-dopaminergic approach—targeting phosphodiesterase 10A t...

– Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year – – Generally well-tolerated with low rates of adverse events and discontinu...

MapLight Therapeutics (Nasdaq: MPLT) reported second quarter 2026 results and a business update, highlighting positive topline data from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia. The study met its primary endpoint, showing a statistically significant and clinically meaningful PANSS total score reduction at Week 5 versus placebo at the 210/3 mg twice-daily dose, plus improvements on prespecified cognitive and key secondary endpoints, with a generally well-tolerated safety profile. MapLight plans an End-of-Phase 2 FDA meeting and a Phase 3 ZEPHYR-2 trial, with topline results expected in 2028.ML-007C-MA is also in the Phase 2 VISTA trial for Alzheimer’s disease psychosis, which has FDA Fast Track designation and topline data expected in the second half of 2027. The company reported Phase 2 IRIS results for ML-004 in autism spectrum disorder; the trial did not meet its primary endpoint, although a prespecified adolescent subgroup showed clinically meaningful improvements in irritability. MapLight ended the quarter with $351.3 million in cash, cash equivalents and investments and, together with a recent $150 million private placement, expects to fund ML-007C-MA through 2028. Quarterly R&D expenses were $53.4 million, G&A expenses were $10.1 million, and net loss was $60.2 million, all higher than the prior-year period, as the company focuses resources on advancing ML-007C-MA and pauses preclinical and discovery-stage programs.

Schizophrenia - Revisiting symptom dimensions in schizophrenia with exploratory graph analysis